Bio-Technology General Corp. has licensed Societa IndustriaPharmaceutical Italiana S.p.A. of Italy to market its BioLonophthalmic once the hyaluronic-acid based product isapproved.
The New York company has other licensees lined up for otherEuropean countries, including France, Switzerland, Spain andPortugal, as well as the Scandinavian market.
The product will be sold in ready-to-use syringes for use incataract and lens surgeries, corneal transplants and glaucomatherapy.
The company's stock (NASDAQ:BTGC) closed up 13 cents at$8.88 on Tuesday.
(c) 1997 American Health Consultants. All rights reserved.